Enovis Corporation
ENOVEnovis Corporation (ENOV) is a global medical device company specializing in orthopedics, regenerative medicine, and surgical solutions. It provides innovative products designed to improve patient outcomes and enhance healthcare. The company focuses on delivering surgical instruments, implants, and regenerative therapies across various medical specialties.
Company News
John Kleckner, Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on Nov. 25, 2025, signaling potential confidence in the company despite a challenging year with significant quarterly losses.
Enovis Corporation will participate in three investor conferences in August and September 2025, including Canaccord Genuity, Wells Fargo Healthcare, and Baird Global Healthcare Conferences.
Medical technology company Enovis reported Q2 2025 revenue of $564.5 million, up 7% year-over-year, beating analyst estimates. The company raised full-year guidance and saw strong performance in its Reconstructive segment, despite ongoing integration and regulatory challenges.
The orthopedic braces and supports market is projected to grow at a CAGR of 5.04% from 2024 to 2030, driven by the increasing burden of orthopedic conditions, sports-related injuries, and the development of smart and custom-made braces.
Enovis Corporation announced that CEO Matt Trerotola will retire, and the company is actively searching for his successor. Trerotola will remain as an executive advisor for a year to facilitate a smooth transition.
